Skip to main content

Advertisement

SpringerLink
Log in

Edaravone Ameliorates Oxidative Damage Associated with Aβ25-35 Treatment in PC12 Cells

  • Published:
Journal of Molecular Neuroscience Aims and scope Submit manuscript

Abstract

Oxidative damage is an important mediator of Alzheimer’s disease (AD); hence, antioxidant therapy is a potential treatment for AD. Edaravone, a free radical scavenger, has been shown to have neuroprotective properties. The study aimed to examine the effects of edaravone on indicators of Aβ25-35-induced oxidative damage in PC12 cells. PC12 cells were treated with 20, 40, or 80 μM edaravone before treatment with 30 μM Aβ25-35. After treatment, the following assessments were performed: cell viability and aggregation, oxidative stress, mitochondrial peroxidation, generation of reactive oxygen species (ROS), and apoptosis. Aggregation, lactate dehydrogenase activity, malondialdehyde concentrations, mitochondrial peroxidation, ROS levels, and apoptosis were significantly increased in Aβ25-35-treated cells but decreased in the treatment with edaravone 40 and 80 μM. In contrast, intracellular glutathione and superoxide dismutase concentrations were significantly decreased in Aβ25-35-treated cells but increased in the treatment with edaravone 40 and 80 μM. Edaravone ameliorates oxidative damage associated with Aβ25-35 treatment in PC12 cells. Our findings support the continued investigation of edaravone as a potential treatment for AD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Bains JS, Shaw CA (1997) Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Brain Res Rev 25:335–358

    Article  PubMed  CAS  Google Scholar 

  • Boothby LA, Doering PL (2005) Vitamin C and vitamin E for Alzheimer's disease. Ann Pharmacother 39:2073–2080

    Article  PubMed  CAS  Google Scholar 

  • Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3:186–191

    Article  PubMed  Google Scholar 

  • Chang Z, Luo Y, Zhang Y, Wei G (2011) Interactions of Abeta25-35 beta-barrel-like oligomers with anionic lipid bilayer and resulting membrane leakage: an all-atom molecular dynamics study. J Phys Chem B 115:1165–1174

    Article  PubMed  CAS  Google Scholar 

  • Chen H, Wang S, Ding JH, Hu G (2008) Edaravone protects against MPP+ -induced cytotoxicity in rat primary cultured astrocytes via inhibition of mitochondrial apoptotic pathway. J Neurochem 106:2345–2352

    Article  PubMed  CAS  Google Scholar 

  • Dong H, Mao S, Wei J et al (2012) Tanshinone IIA protects PC12 cells from beta-amyloid(25-35)-induced apoptosis via PI3K/Akt signaling pathway. Mol Biol Rep 39:6495–6503

    Article  PubMed  CAS  Google Scholar 

  • Fan J, Zhang N, Yin G et al (2012) Edaravone protects cortical neurons from apoptosis by inhibiting the translocation of BAX and increasing the interaction between 14-3-3 and p-BAD. Int J Neurosci 122(11):665–674. doi:10.3109/00207454.2012.707714

    Article  PubMed  CAS  Google Scholar 

  • Galante D, Corsaro A, Florio T et al (2012) Differential toxicity, conformation and morphology of typical initial aggregation states of Abeta1-42 and Abetapy3-42 beta-amyloids. Int J Biochem Cell Biol 44:2085–2093

    Article  PubMed  CAS  Google Scholar 

  • Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148:1204–1222

    Article  PubMed  CAS  Google Scholar 

  • Kaminsky YG, Marlatt MW, Smith MA, Kosenko EA (2010) Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35). Exp Neurol 221:26–37

    Article  PubMed  CAS  Google Scholar 

  • Lee HP, Zhu X, Casadesus G et al (2010) Antioxidant approaches for the treatment of Alzheimer's disease. Expert Rev Neurother 10:1201–1208

    Article  PubMed  Google Scholar 

  • Maier CM, Chan PH (2002) Role of superoxide dismutases in oxidative damage and neurodegenerative disorders. Neuroscientist 8:323–334

    Article  PubMed  CAS  Google Scholar 

  • Mangialasche F, Polidori MC, Monastero R et al (2009) Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res Rev 8:285–305

    Article  PubMed  CAS  Google Scholar 

  • Martínez E, Navarro A, Ordóñez C, Del Valle E, Tolivia J (2012) Amyloid-beta25-35 induces apolipoprotein D synthesis and growth arrest in HT22 hippocampal cells. J Alzheimers Dis 30:233–244

    PubMed  Google Scholar 

  • Mattson MP (2006) Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid Redox Signal 8:1997–2006

    Article  PubMed  CAS  Google Scholar 

  • Millucci L, Ghezzi L, Bernardini G, Santucci A (2010) Conformations and biological activities of amyloid beta peptide 25-35. Curr Protein Pept Sci 11:54–67

    Article  PubMed  CAS  Google Scholar 

  • Murphy MP, Smith RA (2007) Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 47:629–656

    Article  PubMed  CAS  Google Scholar 

  • Pike CJ, Overman MJ, Cotman CW (1995) Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem 270:23895–23898

    Article  PubMed  CAS  Google Scholar 

  • Reddy PH (2006) Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. J Neurochem 96:1–13

    Article  PubMed  CAS  Google Scholar 

  • Reddy PH (2007) Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. Antioxid Redox Signal 9:1647–1658

    Article  PubMed  CAS  Google Scholar 

  • Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Med 10(Suppl):S10–S17

    Article  PubMed  Google Scholar 

  • Shibata K, Hashimoto T, Nobe K, Hasumi K, Honda K (2011) Neuroprotective mechanisms of SMTP-7 in cerebral infarction model in mice. Naunyn Schmiedeberg’s Arch Pharmacol 384:103–108

    Article  CAS  Google Scholar 

  • Song Y, Li M, Li JC, Wei EQ (2006) Edaravone protects PC12 cells from ischemic-like injury via attenuating the damage to mitochondria. J Zhejiang Univ Sci B 7:749–756

    Article  PubMed  CAS  Google Scholar 

  • Uzun S, Kozumplik O, Folnegović-Smalc V (2011) Alzheimer's dementia: current data review. Coll Antropol 35:1333–1337

    PubMed  CAS  Google Scholar 

  • Wang GH, Jiang ZL, Li YC et al (2011) Free-radical scavenger edaravone treatment confers neuroprotection against traumatic brain injury in rats. J Neurotrauma 28:2123–2134

    Article  PubMed  Google Scholar 

  • Xiong N, Xiong J, Khare G et al (2011) Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease. PLoS One 6:e20677

    Article  PubMed  CAS  Google Scholar 

  • Yamamura M, Miyamoto Y, Mitsuno M et al (2010) Edaravone reduces mitochondrial damage due to reperfusion injury following leg ischemia in rats. Int J Angiol 19:e129–e131

    Article  PubMed  Google Scholar 

  • Yoshida H, Yanai H, Namiki Y, Fukatsu-Sasaki K, Furutani N, Tada N (2006) Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev 12:9–20

    Article  PubMed  CAS  Google Scholar 

  • Yu M, Li S, Leng W, Chen H, Wu Y, Yan L (2010) Protective effects of MCl-186 on oxidative damage in a cell model of Alzheimer's disease. Neural Regen Res 5:1226–1230

    Google Scholar 

  • Zhou Y, Li W, Xu L, Chen L (2011) In Salvia miltiorrhiza, phenolic acids possess protective properties against amyloid beta-induced cytotoxicity, and tanshinones act as acetylcholinesterase inhibitors. Environ Toxicol Pharmacol 31:443–452

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This research was supported by grants from the Shaanxi Science Research Project, China (no. 2010K16-08-02).

Author information

Authors and Affiliations

  1. Department of Neurology, the Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, No. 157 West 5 Road, Xi’an, 710004, Shaanxi Province, China

    Gui-lian Zhang, Yun Du, Li Yao, Hong Sun, Ru Zhang, Ning Bu, Hai-qin Wu, Lei Zhang, Ting-ting Li & Ying-ying Guo

  2. Department of Hematology, the Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, No. 157 West 5 Road, Xi’an, 710004, Shaanxi Province, China

    Wang-gang Zhang

  3. Laboratory Animal Center, Medical School of Xi’an Jiaotong University, Xi’an, Shaanxi Province, China

    Enqi Liu

Authors
  1. Gui-lian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wang-gang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yun Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Li Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hong Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ru Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Enqi Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ning Bu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hai-qin Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Lei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ting-ting Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ying-ying Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Gui-lian Zhang or Wang-gang Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, Gl., Zhang, Wg., Du, Y. et al. Edaravone Ameliorates Oxidative Damage Associated with Aβ25-35 Treatment in PC12 Cells. J Mol Neurosci 50, 494–503 (2013). https://doi.org/10.1007/s12031-013-9973-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12031-013-9973-z

Keywords

Search

Navigation